DHV warns Germany’s draft GKV savings law could raise costs, not cut them

What the DHV is objecting to

At the centre of the DHV’s statement is a narrow but consequential change in the draft law: cannabis flowers would no longer be reimbursed by statutory health insurers. The association says that this is being presented as a savings measure, but that the effect would be the opposite, because patients and doctors would be pushed toward less suitable and potentially more expensive treatment paths.the DHV statement on the draft bill

The group’s argument is straightforward. It says cannabis flowers remain necessary for medical supply in some cases, and that removing reimbursement would not eliminate demand. Instead, it would merely shift the burden elsewhere in the system — either onto patients, who may not be able to pay out of pocket, or onto other forms of care that may not work as well for the people involved.

Why the association says savings may not materialise

The DHV frames its objection as a practical question about costs, not just principle. In its view, if patients lose access to reimbursed flowers, the result may be more expensive treatment elsewhere in the care chain rather than a clean reduction in spending. That is the core of its warning that the draft could generate Mehrkosten instead of savings.

• The draft would remove reimbursement for cannabis flowers under statutory health insurance.
• The DHV says flowers are still needed in medical treatment.
• The association expects higher downstream costs rather than savings.
• The policy debate therefore turns on both medical necessity and budget logic.

How the draft fits into a broader insurance debate

The government bill is presented as an effort to stabilise contributions in the statutory health insurance system. But in the DHV’s reading, the savings logic should not be applied mechanically to cannabis medicine. That is why the association’s statement is aimed not only at the proposed cut, but at the assumption that reimbursement withdrawal automatically equals fiscal discipline.

This is also why the debate has broader significance for German cannabis policy. Only days earlier, Cannabivo’s coverage of how Bundestag debate began to question insurance reimbursement for flowers showed that the issue had already reached the parliamentary level. The DHV statement now adds an organised-sector rebuttal to that political movement.

A policy fight that extends beyond one bill

Although the DHV statement is focused on a specific draft, it lands in a wider environment where German cannabis policy remains contested. Broader reporting in the press has shown that legalization and access questions continue to divide policymakers, with reviews and counter-reviews still shaping the debate around how legal supply is working in practice.German cannabis policy remains divisive The reimbursement question belongs to that same dispute: how much access should be preserved, and who should bear the cost when the state narrows it?

That larger context matters because the draft bill does not concern recreational policy, but medical access. The DHV is effectively saying that if Germany wants a stable and rational health system, it should not solve one accounting problem by creating another one for patients and practitioners.

What readers should watch next

The immediate question is whether the draft survives in its current form or whether lawmakers amend the reimbursement provision before it advances. For the DHV, the target is clear: keep cannabis flowers within the scope of statutory coverage where they are medically needed, and reject the assumption that cutting reimbursement will necessarily stabilise contributions.

1. Watch whether lawmakers keep the reimbursement cut in the draft.
2. Track whether the health-policy argument shifts from savings to patient access.
3. Look for further statements from medical and patient groups on the practical impact.
4. Monitor whether the insurance debate becomes part of the broader cannabis-policy review.